AORT vs. STVN, IRTC, BLCO, GKOS, TMDX, NVST, SLNO, LIVN, WRBY, and EYE
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Envista (NVST), Soleno Therapeutics (SLNO), LivaNova (LIVN), Warby Parker (WRBY), and National Vision (EYE). These companies are all part of the "medical equipment" industry.
Artivion vs. Its Competitors
Artivion (NYSE:AORT) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.
Stevanato Group has a net margin of 11.73% compared to Artivion's net margin of -4.43%. Stevanato Group's return on equity of 10.34% beat Artivion's return on equity.
Stevanato Group has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Artivion presently has a consensus target price of $43.97, indicating a potential upside of 4.06%. Given Artivion's stronger consensus rating and higher possible upside, research analysts plainly believe Artivion is more favorable than Stevanato Group.
86.4% of Artivion shares are owned by institutional investors. 7.6% of Artivion shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Artivion had 8 more articles in the media than Stevanato Group. MarketBeat recorded 9 mentions for Artivion and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.75 beat Artivion's score of 0.29 indicating that Stevanato Group is being referred to more favorably in the news media.
Artivion has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
Summary
Stevanato Group beats Artivion on 9 of the 16 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Artivion Competitors List
Related Companies and Tools
This page (NYSE:AORT) was last updated on 10/16/2025 by MarketBeat.com Staff